India's Serology Institute said yesterday that this year it plans to produce up to 60 million doses of a possible vaccine against the emerging coronavirus, undergoing clinical trials in Britain.
The Indian Sera Institute is the world's largest maker of sera in the world, and is a candidate for mass production of the vaccine developed by Oxford University, which began its experiment with humans last week, and is one of the pioneers in the global race to create a vaccine against the emerging corona virus.
Although the Sera Institute vaccine against Covid-19 has not yet been proven effective, the Sera Company has decided to start its manufacture, after it has proven successful in animal experiments and has started experimenting in humans, said the CEO of the Serology Institute, who ran Punawala. The Oxford vaccine is called "CHADOX1N Covid-19".
Bunwala added that he hoped to successfully test the Oxford vaccine, which is scheduled to end around September.
Oxford scientists said, last week, the main focus of preliminary trials is to confirm not only whether the vaccine is working, but whether it stimulates good immune responses, and has no unacceptable side effects.
And recorded about 3.05 million people worldwide, in addition to the death of 211 thousand and 376 others due to «Covid-19», a respiratory disease caused by the virus «Corona».
The institute is the world's largest vaccine maker by volume.